stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Shares outstanding
Harmony Biosciences Holdings, Inc.'s shares outstanding at the end of fiscal 2025 was $58.5M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $59.7M. Over the past ten years it has ranged from $7.8M (fiscal 2019) to $63.7M (fiscal 2018); the current reading is higher than 50% of that period. Harmony Biosciences Holdings, Inc. ranks 265th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $58.5M | 1.17% |
| FY2024 | $57.9M | (4.15%) |
| FY2023 | $60.4M | (1.19%) |
| FY2022 | $61.1M | 3.20% |
| FY2021 | $59.2M | 129.73% |
| FY2020 | $25.8M | 231.39% |
| FY2019 | $7.8M | (87.79%) |
| FY2018 | $63.7M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $59.7M | 1.57% |
| Jun 2026 | $58.8M | (0.04%) |
| Mar 2026 | $58.8M | 0.40% |
| Dec 2025 | $58.5M | (0.30%) |
| 25 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| VIR Vir Biotechnology, Inc. compare | $169.3M |
| TRVI Trevi Therapeutics, Inc. compare | $156.6M |
| SRPT Sarepta Therapeutics, Inc. compare | $105.9M |
| REPL Replimune Group, Inc. compare | $105.2M |
| FTRE Fortrea Holdings Inc. compare | $101.2M |
| MESO Mesoblast Limited compare | $77.8M |
| HRMY Harmony Biosciences Holdings, Inc. | $59.7M |
| MAZE Maze Therapeutics, Inc. compare | $59.0M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $35.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item